Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Genotyping of Human Leukocyte Antigen (HLA) Ancestral Haplotypes as Prognostic Marker in Cancer Using PCR Analysis

  • Protocol
  • First Online:
Molecular Diagnostics for Melanoma

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1102))

  • 4718 Accesses

Abstract

The major histocompatibility complex (MHC) comprises a set of genes that are essential to immunity and surveillance against neoplastic transformation. MHC antigens not only regulate antitumor immune responses in experimental animal models but also directly correlate with survival and prognosis of patients with various types of cancers. Effective recognition of tumor cells by effector T cells may be affected by the genotype and the extent of expression of human leukocyte antigen (HLA)-peptide complexes. Therefore, MHC antigens may serve as potential biomarkers for prognosis and allow selection of cancer patients for specific therapy. We describe PCR-based method to determine the HLA genotype in healthy individuals and patients using blood and tumor tissue as DNA source.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

HLA:

Human leucocyte antigen

MHC:

Major histocompatibility complex

APM:

Antigen presenting machinery

AHH:

Ancestral HLA haplotype

PCR:

Polymerase chain reaction

MM:

Malignant melanoma

EOC:

Epithelial ovarian cancer

OS:

Overall survival

TTM1:

Time from diagnosis to first metastasis

SFM1:

Survival time from metastasis

FFPE:

Formalin fixed paraffin embedded

PBL:

Peripheral blood lymphocytes

References

  1. Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M (1985) Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315(6017):301–305

    Article  PubMed  CAS  Google Scholar 

  2. Hoon DS, Okamoto T, Wang HJ, Elashoff R, Nizze AJ, Foshag LJ, Gammon G, Morton DL (1998) Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients? J Clin Oncol 16(4):1430–1437

    PubMed  CAS  Google Scholar 

  3. Lee JE, Abdalla J, Porter GA, Bradford L, Grimm EA, Reveille JD, Mansfield PF, Gershenwald JE, Ross MI (2002) Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol 9(6):587–593

    PubMed  Google Scholar 

  4. Onishi T, Ohishi Y, Iizuka N, Imagawa K (1996) Phenotype frequency of human leukocyte antigens in Japanese patients with renal cell carcinoma who responded to interferon-alpha treatment. Int J Urol 3(6):435–440

    Article  PubMed  CAS  Google Scholar 

  5. Franzke A, Buer J, Probst-Kepper M, Lindig C, Framzle M, Schrader AJ, Ganser A, Atzpodien J (2001) HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer. Cancer Biother Radiopharm 16(5):401–409

    Article  PubMed  CAS  Google Scholar 

  6. Bain C, Merrouche Y, Puisieux I, Blay JY, Negrier S, Bonadona V, Lasset C, Lanier F, Duc A, Gebuhrer L, Philip T, Favrot MC (1997) Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. Br J Cancer 75(2):283–286

    Article  PubMed  CAS  Google Scholar 

  7. So T, Takenoyama M, Sugaya M, Yasuda M, Eifuku R, Yoshimatsu T, Osaki T, Yasumoto K (2001) Unfavorable prognosis of patients with non-small cell lung carcinoma associated with HLA-A2. Lung Cancer 32(1):39–46

    Article  PubMed  CAS  Google Scholar 

  8. Tisch M, Kyrberg H, Weidauer H, Mytilineos J, Conradt C, Opelz G, Maier H (2002) Human leukocyte antigens and prognosis in patients with head and neck cancer: results of a prospective follow-up study. Laryngoscope 112(4):651–657

    Article  PubMed  CAS  Google Scholar 

  9. Townsend ARM, Gotch FM, Davey J (1985) Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 42(2):457

    Article  PubMed  CAS  Google Scholar 

  10. Sioud M (2009) Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines? Scand J Immunol 70(6):516–525

    Article  PubMed  CAS  Google Scholar 

  11. Campoli M, Ferrone S (2008) Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens 72(4):321–334

    Article  PubMed  CAS  Google Scholar 

  12. Algarra I, Collado A, Garrido F (1997) Protein bound polysaccharide PSK abrogates more efficiently experimental metastases derived from H-2 negative than from H-2 positive fibrosarcoma tumor clones. J Exp Clin Cancer Res 16(4):373–380

    PubMed  CAS  Google Scholar 

  13. Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, Seliger B, Masucci GV (2012) Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother 61:1243–1253

    Google Scholar 

  14. Browning M, Dunnion D (1997) HLA and cancer: implications for cancer immunotherapy and vaccination. Eur J Immunogenet 24(4):293–312

    Article  PubMed  CAS  Google Scholar 

  15. Blomhoff A, Olsson M, Johansson S, Akselsen HE, Pociot F, Nerup J, Kockum I, Cambon-Thomsen A, Thorsby E, Undlien DE, Lie BA (2006) Linkage disequilibrium and haplotype blocks in the MHC vary in an HLA haplotype specific manner assessed mainly by DRB1*03 and DRB1*04 haplotypes. Genes Immun 7(2):130–140

    Article  PubMed  CAS  Google Scholar 

  16. Reich DE, Cargill M, Bolk S, Ireland J, Sabeti PC, Richter DJ, Lavery T, Kouyoumjian R, Farhadian SF, Ward R, Lander ES (2001) Linkage disequilibrium in the human genome. Nature 411(6834):199–204

    Article  PubMed  CAS  Google Scholar 

  17. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D (2002) The structure of haplotype blocks in the human genome. Science 296(5576):2225–2229

    Article  PubMed  CAS  Google Scholar 

  18. Alper CA, Larsen CE, Dubey DP, Awdeh ZL, Fici DA, Yunis EJ (2006) The haplotype structure of the human major histocompatibility complex. Hum Immunol 67(1–2):73

    Article  PubMed  CAS  Google Scholar 

  19. Johnson GC, Esposito L, Barratt BJ, Smith AN, Heward J, Di Genova G, Ueda H, Cordell HJ, Eaves IA, Dudbridge F, Twells RC, Payne F, Hughes W, Nutland S, Stevens H, Carr P, Tuomilehto-Wolf E, Tuomilehto J, Gough SC, Clayton DG, Todd JA (2001) Haplotype tagging for the identification of common disease genes. Nat Genet 29(2):233–237

    Article  PubMed  CAS  Google Scholar 

  20. Degli-Esposti MA, Leaver AL, Christiansen FT, Witt CS, Abraham LJ, Dawkins RL (1992) Ancestral haplotypes: conserved population MHC haplotypes. Hum Immunol 34(4):242

    Article  PubMed  CAS  Google Scholar 

  21. The MHC sequencing consortium (1999) Complete sequence and gene map of a human major histocompatibility complex. Nature 401(6756):921–923

    Article  Google Scholar 

  22. Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, Lush MJ, Povey S, Talbot CC Jr, Wright MW, Wain HM, Trowsdale J, Ziegler A, Beck S (2004) Gene map of the extended human MHC. Nat Rev Genet 5(12):889–899

    Article  PubMed  CAS  Google Scholar 

  23. Thorsby E (1997) Invited anniversary review: HLA associated diseases. Hum Immunol 53(1):1–11

    Article  PubMed  CAS  Google Scholar 

  24. Gamzatova Z, Villabona L, Dahlgren L, Dalianis T, Nillson B, Bergfeldt K, Masucci GV (2006) Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecol Oncol 103(1):145–150

    Article  PubMed  CAS  Google Scholar 

  25. De Petris L, Bergfeldt K, Hising C, Lundqvist A, Tholander B, Pisa P, Van Der Zanden HG, Masucci G (2004) Correlation between HLA-A2 Gene Frequency, Latitude, Ovarian and Prostate Cancer Mortality Rates. Med Oncol 21(1):49–52

    Article  PubMed  Google Scholar 

  26. Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, Seliger B, Masucci GV (2012) Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. (2012). Cancer Immunol Immunother 61(8):1243–1253

    Article  PubMed  CAS  Google Scholar 

  27. Nowak J, Kalinka-Warzocha E, Juszczynski P, Bilinski P, Mika-Witkowska R, Zajko M, Bienvenu J, Coiffier B, Salles G, Warzocha K (2007) Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin’s lymphoma. Genes Chromosomes Cancer 46(5):500–507

    Article  PubMed  CAS  Google Scholar 

  28. Helgadottir H, Andersson E, Villabona L, Kanter L, van der Zanden H, Haasnoot GW, Seliger B, Bergfeldt K, Hansson J, Ragnarsson-Olding B, Kiessling R, Masucci GV (2009) The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma. Cancer Immunol Immunother 58(10):1599–1608

    Article  PubMed  CAS  Google Scholar 

  29. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3(11):999–1005

    Article  PubMed  CAS  Google Scholar 

  30. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11):991–998

    Article  PubMed  CAS  Google Scholar 

  31. Kim R, Emi M, Tanabe K (2007) Cancer immunoediting from immune surveillance to immune escape. Immunology 121(1):1–14

    Article  PubMed  CAS  Google Scholar 

  32. Cabrera T, Lara E, Romero JM, Maleno I, Real LM, Ruiz-Cabello F, Valero P, Camacho FM, Garrido F (2007) HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother 56(5):709–717

    Article  PubMed  CAS  Google Scholar 

  33. Anichini A, Mortarini R, Nonaka D, Molla A, Vegetti C, Montaldi E, Wang X, Ferrone S (2006) Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res 66(12):6405–6411

    Article  PubMed  CAS  Google Scholar 

  34. Maeurer MJ, Gollin SM, Storkus WJ, Swaney W, Karbach J, Martin D, Castelli C, Salter R, Knuth A, Lotze MT (1996) Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin Cancer Res 2(4):641–652

    PubMed  CAS  Google Scholar 

  35. Schipper RF, D’Amaro J, Bakker JT, Bakker J, van Rood JJ, Oudshoorn M (1997) HLA gene haplotype frequencies in bone marrow donors worldwide registries. Hum Immunol 52(1):54–71

    Article  PubMed  CAS  Google Scholar 

  36. Schipper RF, D’Amaro J, de Lange P, Schreuder GM, van Rood JJ, Oudshoorn M (1998) Validation of haplotype frequency estimation methods. Hum Immunol 59(8):518–523

    Article  PubMed  CAS  Google Scholar 

  37. Svejgaard A, Ryder LP (1994) HLA and disease associations: detecting the strongest association. Tissue Antigens 43(1):18–27

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

These studies were mainly supported by grants from the Cancer Society in Stockholm and the King Gustaf V Jubilee Fund and the Swedish Cancer Society, the Karolinska Institute/Stockholm County ALF grant. Sequences for HLA-A2 primers were kindly provided by Dr. Olle Olerup at Olerup SSP AB.

Author information

Authors and Affiliations

  1. Department of Oncology-Pathology, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden

    Lisa Villabona, Emilia Andersson, Maddalena Marchesi & Giuseppe V. Masucci

Authors
  1. Lisa Villabona
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emilia Andersson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maddalena Marchesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuseppe V. Masucci
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cancer Diagnosis Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

    Magdalena Thurin

  2. Sidra Medical and Research Center,Qatar Foundation, Doha, Qatar

    Francesco M. Marincola

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media, New York

About this protocol

Cite this protocol

Villabona, L., Andersson, E., Marchesi, M., Masucci, G.V. (2014). Genotyping of Human Leukocyte Antigen (HLA) Ancestral Haplotypes as Prognostic Marker in Cancer Using PCR Analysis. In: Thurin, M., Marincola, F. (eds) Molecular Diagnostics for Melanoma. Methods in Molecular Biology, vol 1102. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-727-3_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-727-3_18

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-726-6

  • Online ISBN: 978-1-62703-727-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation